

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Joachim BRENDEL et al.**

Examiner: R. Desai

Art Unit: 1625

Application No.: 10/691,624

Filed: October 24, 2003

Title: **2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM**

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

August 9, 2005

Date of Transmission

Signature

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
CENTRAL FAX CENTER

AUG 09 2005

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.


- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☒ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The reference, *Pharmakologie und Toxikologie*, describes the class III antiarrhythmics Amiodaron and Sotalol, which are K<sup>+</sup>-channel blockers. The reference describes the chemical structures of Amiodaron and Sotalol, the mode of action, the application, the pharmacokinetic and the side effects.

Respectfully submitted,

  
\_\_\_\_\_  
Joseph D. Rossi, Reg. No. 47,038  
Attorney for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3410  
Telefax (908) 231-2626  
Aventis Docket No. DEAV1999/L060 US NP2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Joachim BRENDDEL et al.**


Examiner: R. Desai

Application No.: 10/691,624

Art Unit: 1625

Filed: October 24, 2003

Title: **2'-SUBSTITUTED 1, 1'-BIPHENYL-2-CARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM**

Certificate of Mailing or Transmission	
I hereby certify that this correspondence is being being facsimile transmitted to the USPTO, on the date indicated below.	
Date of Deposit	<u>AUGUST 9, 2005</u>
Printed Name of Person Signing Certificate	<u>Paul Irvine</u>
Signature	

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


**RECEIVED**  
**CENTRAL FAX CENTER**

**AUG 09 2005**

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

  
\_\_\_\_\_  
Joseph D. Rossi, Reg. No. 47,038  
Attorney for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3410  
Telefax (908) 231-2626

Aventis Docket No. DEAV1999/L060 US NP2



